This article is a correction to:
Endoglin aggravates peritoneal fibrosis by regulating the activation of TGF-β/ALK/Smads signaling
Qian Huang
Rui Xiao
Jing Lu
Yao Zhang2
Jie Gao
Haiping Wang- 1Department of Nephrology, Shandong Provincial Hospital, Shandong University, Jinan, China
- 2Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
A Corrigendum on
Endoglin aggravates peritoneal fibrosis by regulating the activation of TGF-β/ALK/Smads signaling
by Huang Q, Xiao R, Lu J, Zhang Y, Xu L, Gao J, Sun J and Wang H (2022). Front. Pharmacol. 13:973182. doi: 10.3389/fphar.2022.973182
In the published article, there was an error in the Funding statement. Some information were erroneously omitted from the statement. The original statement stated: This research was funded by National Science Foundation for Young Scholars of China (Grant Nos. 81500584 and 81200530) and the Science and Technology Development Plan Program of Medicine and Health of Shandong Province (No. 202103050761). The correct Funding statement appears below.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by National Science Foundation for Young Scholars of China (Grant Nos 81500584 and 81200530), the Science and Technology Development Plan Program of Medicine and Health of Shandong Province (No. 202103050761), Jinan Science and Technology Development Plan - Clinical Medicine Technology Innovation Plan (No. 202225049) and Young Scientist Fund Training Program of Shandong First Medical University (Shandong Academy of Medical Sciences) (No. 202201-062).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: endoglin, peritoneal fibrosis, angiogenesis, EMT, TGF-β/ALK/Smads
Citation: Huang Q, Xiao R, Lu J, Zhang Y, Xu L, Gao J, Sun J and Wang H (2024) Corrigendum: Endoglin aggravates peritoneal fibrosis by regulating the activation of TGF-β/ALK/Smads signaling. Front. Pharmacol. 15:1532797. doi: 10.3389/fphar.2024.1532797
Received: 22 November 2024; Accepted: 25 November 2024;
Published: 12 December 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Huang, Xiao, Lu, Zhang, Xu, Gao, Sun and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jing Sun, c2RkaWFseXNpc0AxMjYuY29t; Haiping Wang, Y2t0d2hwdnZ2QDE2My5jb20=
†These authors have contributed equally to this work and share first authorship